Lululemon downgraded to Market Perform from Outperform at CICC

CICC analyst Mingkai Zhuang downgraded Lululemon (LULU) to Market Perform from Outperform with a $280.49 price target
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

18 minutes ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

18 minutes ago

• Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

33 minutes ago

• Business Insider

J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)

In a report released on June 20, Anupam Rama from J.P. Morgan maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $8.50. The company's shares closed last Friday at $9.30. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Rama has an average return of -6.9% and a 37.70% success rate on recommended stocks. SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $9.04, which is a -2.80% downside from current levels. In a report released on June 20, Robert W. Baird also maintained a Hold rating on the stock with a $9.00 price target. The company has a one-year high of $13.47 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.52M.